Breakthrough Blood Tests for Early Multi-Cancer Detection

Researchers at UCLA have developed a low-cost blood test capable of detecting multiple types of cancer and various organ abnormalities from a single sample. The method, known as MethylScan, analyzes genome-wide methylation of cell-free DNA (cfDNA) circulating in the bloodstream to identify signals associated with liver, lung, ovarian, and stomach cancers, as well as non-cancerous liver conditions.

According to a report published April 6, 2026, the test demonstrates a high level of overall accuracy. At a specificity of 98%, which indicates a low rate of false positives, the test detected approximately 63% of cancers across all stages and roughly 55% of early-stage cancers.

The Science of Cell-Free DNA

MethylScan operates by examining cfDNA, which consists of tiny fragments of genetic material released into the blood when cells die. Because cells from every organ shed DNA into the bloodstream, these fragments carry molecular signals that reflect the health and status of organs throughout the body.

Every day, 50 to 70 billion cells in our body die. They don’t just disappear, their DNA goes into the bloodstream. That means we already have information from all our organs circulating in the blood.

Dr. Jasmine Zhou, professor of pathology and laboratory medicine and investigator at the UCLA Health Jonsson Comprehensive Cancer Center

Dr. Zhou, the study’s senior author, emphasized the importance of early detection in improving patient outcomes. She noted that survival rates are significantly higher when cancers are identified before they spread, stating that if you detect cancer at stage one, outcomes are dramatically better than at stage four.

The Landscape of Multi-Cancer Early Detection

The UCLA development is part of a broader movement toward multi-cancer early detection (MCED) tests. These tools are designed to complement existing single-cancer screening protocols by interrogating cfDNA for shared cancer signals across various tumor types.

Another example of this technology is the Galleri test, which screens for a signal shared by more than 50 types of cancer using a single blood test. The Galleri test identifies DNA shed by cancer cells in the bloodstream and is intended to find the fingerprint of deadly cancers before they become symptomatic, including those for which no recommended screening tests currently exist.

Recent advances in genome sequencing and machine learning have accelerated the development of these MCED tests. Reporting in the journal Nature highlighted real-world instances where an MCED test detected cancer signals in individuals who were subsequently diagnosed with kidney, ovary, and head/neck cancers—types that lack standardized screening guidelines.

Addressing the Screening Gap

The push for MCED technology stems from a significant gap in current public health guidelines. The United States Preventive Services Task Force (USPSTF) recommends single-cancer screening for only a select few malignancies, including breast, cervical, colorectal, and lung cancers.

Despite the effectiveness of these targeted tests, approximately 70% of cancer deaths in the United States among individuals aged 50 to 79 are caused by cancers that do not have USPSTF-recommended screening. This gap contributes to a national cancer mortality rate exceeding 600,000 cases per year.

The potential for extremely early detection is further evidenced by research from Johns Hopkins Medicine. In a report released June 4, 2025, investigators found that for six out of eight individuals, cancers could be detected in the bloodstream between 3.1 and 3.5 years prior to the actual clinical diagnosis.

Limitations and Clinical Application

While promising, medical researchers and providers caution that MCED tests are not a replacement for traditional screenings. For instance, the Galleri test is intended to be used in addition to healthcare provider-recommended screening tests.

Several limitations remain inherent to liquid biopsies:

• False positive and false negative results can occur.
• Not all cancers shed detectable signals into the blood.
• The tests do not predict future genetic risk for cancer.

The goal of these emerging blood tests is to provide a more affordable and comprehensive approach to health monitoring, potentially catching malignancies at an early, curable stage before symptoms appear.